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Abstract Oxidised lipids, covering enzymatic and auto-
oxidation-synthesised mediators, are important signalling me-
tabolites in inflammation while also providing a readout for
oxidative stress, both of which are prominent physiological
processes in a plethora of diseases. Excretion of these metab-
olites via urine is enhanced through the phase-II conjugation
with glucuronic acid, resulting in increased hydrophilicity of
these lipid mediators. Here, we developed a bovine liver-β-
glucuronidase hydrolysing sample preparation method, using
liquid chromatography coupled to tandem mass spectrometry
to analyse the total urinary oxidised lipid profile including the
prostaglandins, isoprostanes, dihydroxy-fatty acids, hydroxy-
fatty acids and the nitro-fatty acids. Our method detected more
than 70 oxidised lipids biosynthesised from two non-
enzymatic and three enzymatic pathways in urine samples.
The total oxidised lipid profiling method was developed and
validated for human urine and was demonstrated for urine
samples from patients with rheumatoid arthritis. Pro-
inflammatory mediators PGF2α and PGF3α and oxidative
stress markers iPF2α- IV, 11-HETE and 14-HDoHE were pos-
itively associated with improvement of disease activity score.
Furthermore, the anti-inflammatory nitro-fatty acids were neg-
atively associated with baseline disease activity. In conclu-
sion, the developed methodology expands the current meta-
bolic profiling of oxidised lipids in urine, and its application
will enhance our understanding of the role these bioactive
metabolites play in health and disease.
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Introduction
Oxidised lipids are important signalling mediators in health
and disease, capable of providing quantitative readouts relat-
ing to inflammatory and oxidative stress status. The de novo
synthesis of oxidised lipids can be broadly divided into enzy-
matic and auto-oxidation pathways. The auto-oxidation path-
way of oxidised lipids is interlinked with reactive oxygen
species (ROS) or reactive nitrogen species (RNS), leading to
the peroxidation of fatty acids in membrane-bound phospho-
lipids and producing the isoprostanes (IsoPs) [1, 2] or nitro-
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fatty acids (NO2-FAs) [3]. The lipid peroxidation readout from
IsoPs are considered the golden standard for measuring oxi-
dative stress in biological systems [4, 5]. Interestingly, NO2-
FAs potentiate diverse anti-inflammatory signalling actions
regarded as beneficial within health and disease [3]. These
peroxidised lipids impair membrane and organelle integrity
and are subsequently excreted from the cell into systemic cir-
culation via cellular repair mechanisms [1].
The enzymatic routes include: (i) cyclooxygenase-I/
II(COX-I/II), synthesising the prostaglandins (PGs); (ii) 5-/
12-/15-lipoxygenase (5-/12-/15-LOX), synthesising leukotri-
enes, lipoxins and hydroxyl-fatty acids; and lastly, (iii) cyto-
chrome P450 (CYP450) responsible for the synthesis of
epoxy-fatty acids and dihydroxy-fatty acids [6]. These enzy-
matically oxidised lipids are synthesised locally from essential
free fatty acids and act as signalling mediators in immune
modulation and inflammatory responses [6–9]. Due to the
potent biological signalling activity of enzymatically oxidised
lipids, the active mediators are short-lived in systemic circu-
lation where they are actively metabolised prior to excretion
[10]. Thus taking serum and/or plasma as a representative
snapshot of the systemic circulation might not be the most
suitable approach to study the oxidised lipid profile. Urine,
on the other hand, is a non-invasive bio-fluid, which contains
the collected excreted downstream metabolic products. These
downstreammetabolites provide an enriched systemic readout
and are indicative of the presence of the active upstream
mediators.
Urine does present some sample specific complica-
tions for analysis, such as rather large variations in me-
tabolite concentration, limited solubilities of apolar me-
tabolites and conjugation of some metabolites. These
complexities are even more prominent during the analy-
ses of lipid-like metabolites in urine. Due to the partial
hydrophobic nature, oxidised lipids are often conjugated
to increase their hydrophilicity, mainly by phase-II me-
tabolism located in the liver [11]. Phase-II metabolism
comprises different enzymatic conjugation reactions, with
oxidised lipids most commonly conjugated with glucu-
ronic acid (GlcA) via UDP-glucuronosyltransferases
[12–18]. Effectively, the oxidised lipids can be excreted
in different forms via urine: the unconjugated (free) and
the conjugated species [14, 16]. Actually, the GlcA-
conjugated oxidised lipids represent a more hydrophilic
form of the metabolites.
Robust metabolic profiling of urinary oxidised lipids
has been reported using either gas- or liquid chromatog-
raphy coupled to mass spectrometry [4, 19–27]. However,
these methods either detected metabolites in their free
form (neglecting the conjugated forms) or focused on a
subset of IsoPs and/or PGs. These methodologies lack the
broad scope of compounds necessary for a more thorough
understanding of disease pathophysiology. Two recent
methods reporting on the total (free + conjugated) IsoPs
and PGs levels showed increasing urinary metabolite con-
centrations ranging from 36 to 100 % [15, 28], indicating
the significant increases when measuring the total concen-
tration, but these methods excluded the LOX and
CYP450-oxidised lipid metabolites. Therefore, it is neces-
sary to develop a method able to measure the total urinary
oxidised lipids covering the three enzymatic synthesis
routes as well as the auto-oxidation metabolites, broaden-
ing its biological range.
In the present study, we developed and validated robust
methods for measuring both the free and total levels of
oxidised lipids in human urine samples, covering the PGs,
IsoPs, hydroxyl-fatty acids, epoxy-fatty acids, leukotrienes,
lipoxins and NO2-FAs. To measure the total oxidised urinary
profile, we investigated the suitability of three different β-
glucuronidase enzymes derived from Helix pomatia,
Escherichia coli and bovine liver. We evaluated these by de-
termining the increase in free metabolites, metabolite stability
and enzyme blank effect. Bovine liver derived β-
glucuronidase was chosen as the preferred hydrolysing agent
and was used in the total oxidised lipid method and validated
concurrently with the free oxidised lipid method.
Furthermore, we evaluated the benefit of total level oxidised
lipid analyses in urine of rheumatoid arthritis patients. The
methodology we established covers a broad scope of oxidised
lipid, which enables further investigation of the function and
mechanism of these lipids in both health and disease.
Materials and methods
Chemicals and reagents
Ultra-performance liquid chromatography (UPLC)-grade ace-
tonitrile, isopropanol, methanol, ethyl acetate and purified wa-
ter were purchased from Biosolve B.V. (Valkenswaard, the
Netherlands). Acetic acid, ammonium hydroxide, ammonium
acetate and 2-proponal were acquired from Sigma-Aldrich
(Zwijndrecht, the Netherlands). Sodium dihydrogen phos-
phate dihydrate, sodium hydrogen phosphate and sodium ac-
etate were obtained from Merck (Darmstadt, Germany).
β-glucuronidase enzymes
β-glucuronidase (GUS) from (1) H. pomatia type H-2 (aque-
ous solution, ≥85,000 units/mL), (2) E. coli IX-A (lyophilised
power, 1,000,000–5,000,000 units/g) and (3) bovine liver B-1
(solid, ≥1,000,000 units/g), together with the exogenous sub-
strate of GUS 4-methylumbelliferyl β-D-glucopyranoside
(MUG) were purchased from Sigma-Aldrich Corporation
(St. Louis, MO, USA).
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Standards and internal standard solutions
Standards and deuterated standards were purchased from
Cayman Chemicals (Ann Arbor, MI, USA), Bio-mol
(Plymouth Meeting, PA, USA) or Larodan (Malmö,
Sweden). Standard and deuterated standard solutions were
prepared in methanol containing butylated hydroxy-toluene
(BHT) (0.2 mg BHT/EDTA), stored at −80 °C. Electronic
supplementary material (ESM) Table S1 lists an overview of
the deuterated internal standards (ISTDs) used in this study.
Urine sample collection
Collection of control urine for method development
Morning urine was obtained from ten volunteers (five males
and five females) age 27 to 32. The urine samples were
pooled, mixed and 400 μL were aliquoted into 2 mL
Eppendorf tubes and immediately stored at −80 °C prior to
extraction.
Rheumatoid arthritis patients
Oxidised lipid profiling was performed on urine samples de-
rived from an observational study—BiOCURA [29]. In
BiOCURA, rheumatoid arthritis (RA) patients eligible for bi-
ological disease-modifying anti-rheumatic drugs
(bDMARDs) were recruited, and urine samples were collect-
ed at random times as baseline samples before initiating
bDMARD therapy. Clinical parameters and demographic data
were also collected at the start of the study as baseline infor-
mation, including disease activity measured in 28 joints
(DAS28), C-reactive protein (CRP), age, sex, BMI, smoking
status, alcohol consumption and concomitant DMARDs. The
study was approved by the ethics committee of the University
Medical Centre Utrecht and the institutional review boards of
the participating centres. Human material and human data
were handled in accordance with the Declaration of
Helsinki, and written informed consent was obtained from
each patient.
Our analysis was restricted to the BiOCURA patients with
a baseline (before bDMARDs treatment) disease activity score
of >2.6 and good or no drug response after 3 months with
Etanercept (ETN) or Adalimumab (ADA) based on the
EULAR response criteria. EULAR good response is defined
as an improvement in DAS28 > 1.2 and a present DAS28 ≤
3.2, whereas a EULAR non-response is assigned to patients
with an improvement of 0.6–1.2 with present DAS28 > 5.1 or
patients with an improvement ≤0.6. In the end, 40 subjects (20
good responders, 20 non-responders) with ETN and 40 sub-
jects (20 good responders, 20 non-responders) with ADA
were included in the present study. ETN and ADA are tumor
necrosis factor (TNF)-α inhibitors, which is the most widely
used category of bDMARDs.
Methodology development for optimising enzymatic
hydrolysis
Hydrolysis conditions were optimised for each of the three
GUSs following the approach in ESM Fig. S1. Parameters in-
cluded enzyme concentration (1000, 1500 and 2000 U/sample),
incubation temperature (37 and 55 °C) and time (2, 6, 12 and
24 h). The obtained experimental results for the three enzymes
were used to determine the optimal hydrolysing conditions.
Enzymatic hydrolysing conditions
Literature was used to guide the selection of the optimal hy-
drolysing conditions for the three selected candidate enzymes
with regard to the used buffer composition and pH [18, 30,
31]. For both, H. pomatia and bovine liver GUS, a 200-mM
acetate buffer (pH 4.5) was used for hydrolysis, and for E. coli
GUS, a hydrolysis buffer of 75 mM phosphate buffer (pH 6.8)
was used. As a sensitive GUS substrate, MUG was added into
each urine sample as a positive control for monitoring GUS
activity.
Enzymatic hydrolysis procedure for GlcA-conjugated oxidised
lipids
Ice-thawed urine samples (400 μL each) were immediately
treated with 10 μL antioxidants (0.2 mg BHT/EDTA) and
spiked with 20 μL ISTDs and 5 μL MUG solution. Next,
200 μL of the specific enzyme solution in its appropriate buff-
er was added to the sample, and the mixture was vortexed and
incubated. After hydrolysis, samples were put on ice prior to
oxidised lipid extraction.
Total and free urinary oxidised lipid extraction
For both, total and free oxidised lipids, the extraction was
performed by the same ethyl acetate liquid-liquid
extraction (LLE) procedure. For the analyses of the free
oxidised lipids, 400 μL urine were spiked with 10 μL antiox-
idants and 20 μL ISTDs, similar to the description of enzy-
matic hydrolysed (total) samples in BEnzymatic hydrolysis
procedure for GlcA-conjugated oxidised lipids^.
Subsequently, 200 μL citric acid/phosphate buffer (pH 3)
was added to the total and free urine samples, and oxidised
lipids were extracted by adding 1 mL ethyl acetate followed
by shaking for 1 min. Samples were centrifuged at 13,000 rpm
for 10 min (4 °C), after which 800 μL upper organic phase
was transferred to a new Eppendorf tube. The LLE was re-
peated for a second time, and the collected organic phase was
evaporated to dryness in Labconco CentriVap concentrator
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(Kansas City, MO, USA). The residues were reconstituted
with 30 μL solution of 70 % methanol solution containing
100 nM 1-cyclohexyluriedo-3-dodecanoic acid (CUDA) as
an external quality marker for the analysis. Afterwards, the
extracts were centrifuged at 13,000 rpm for 5 min (4 °C) and
transferred to LC autosampler vials.
Lipid chromatography-mass spectrometry analyses
(LC-MS/MS)
The complete oxidised lipid target lists and corresponding
ISTDs divided per pathway are shown in ESM Table S2, S3,
S4 and S5. The leukotrienes, hydroxyl-fatty acids, epoxy-fatty
acids and lipoxins were analysed by high-performance liquid
chromatography (Agilent 1260, San Jose, CA, USA) coupled
to a triple-quadrupole mass spectrometer (Agilent 6460, San
Jose, CA, USA), using anAscentis® Express column (2.7μm,
2.1 × 150 mm) as detailed in Strassburg et al. [32].
For adequate PG and IsoP isomer resolution, together with
sensitive detection of the NO2-FAs, an optimised chromato-
graphic method was developed in-house. UHPLC-MS/MS
analysis was performed using the Shimadzu LCMS-8050
(Shimadzu, Japan) with a Kromasil EternityXT column
(1.8 μm, 50 × 2.1 mm) maintained at 40 °C. The method used
a three mobile-phase setup with: H2O with 5 mM ammonium
acetate and 0.0625 % ammonium hydroxide (A), methanol
with 0.2 % ammonium hydroxide (B) and isopropanol with
0.2 % ammonium hydroxide (C), with a flow rate of 0.6 mL/
min. The injection volume was 10 μL, and all analytes eluted
during a 10-min ternary gradient with a starting percentage
composition of 94.5:5:0.5 (A/B/C). A chromatographic gradi-
ent is provided in ESM Fig. S2.
The LCMS-8050 consisted of a triple-quadrupole mass
spectrometer with a heated electrospray ionisation (ESI)
source. In negative ion mode, the source parameters were as
follows: the heat block temperature was 400 °C, with the
heating gas at 250 °C and a flow of 10 L/min. The nebulising
and drying gas had a flow rate of 3 and 10 L/min, respectively.
The interface voltage was set at 4 kV with a temperature of
150 °C. The conversion dynode was set at 10 kV, and
desolvation temperature was 250 °C. Analytes were detected
in negative MRM mode.
Method validation
The targeted profiling of oxidised lipids has previously been
validated for plasma samples, and the performance character-
istics linearity, intra- and inter-day precision and accuracy
were reported [32]. In the present study, we used the same
chromatography parameters in terms of the columns, mobile
phase, gradient etc. Therefore, the current validation was per-
formed to determine recovery, matrix effect and precision for
the ISTDs for the reported extraction method.
Creatinine analysis
Urine samples of RA patients were collected at a random time
of day, therefore the amount of liquids consumed influenced
the concentration of the oxidised lipids in the samples. To
eliminate this influence, levels of urinary creatinine were used
to correct for dilution. Creatinine levels were determined
based on a fast creatinine (urinary) assay kit (item no.
500701, Cayman Chemical Company, Ann Arbor, MI, USA).
Data processing and statistical analyses
Peak determination and peak area integration were performed
with Mass Hunter Quantitative Analysis (Agilent, Version
B.04.00) and LabSolutions (Shimadzu, Version 5.65). The
obtained peak areas of targets were first corrected by appro-
priate ISTD and creatinine concentrations (mg/dL), then nor-
malised by log transformation. After data pre-processing, cat-
egorical principal component analysis (CATPCA, ESM
methods) [33] and multiple linear regressions (MLR) were
applied to explore the relationships between oxidised lipids
and clinical parameters. Cytoscape was used to visualise the
associations [34]. All statistical analysis was performed using
IBM SPSS Statistics 23.0 software (Chicago, IL, USA).
Results
Optimisation for the hydrolysis of IsoPs, PGs
and NO2-FAs
For determining the optimal enzymatic deconjugation proce-
dure for urinary oxidised lipids, three GUSs derived from
H. pomatia, E. coli and bovine liver were investigated.
During the method development, critical parameters including
enzyme concentrations, hydrolysis temperature and time were
optimised. In order to simplify the method optimisation, we
focused on the quantification of a pre-selected panel of me-
tabolites to evaluate the method performance, which covers
the most studied IsoPs, PGs and NO2-FAs in human body
fluids. The selected panel consisted of F-series IsoPs (8-iso-
PGF2α, 8-iso-15(R)-PGF2α and 8-iso-13,14-dihydro-PGF2α),
F- and E-series PGs (PGF2α, 13,14-dihydro-PGF2α, PGE1 and
PGE2) and two NO2-FAs mediators (NO2-linoleic acid and
NO2-oleic acid) (see ESM Table S6).
For all three GUSs tested, the optimal conditions was
1000 U enzyme/400 μL urine incubated at 37 °C for 2 h.
No increase in metabolite levels were achieved through in-
creasing the hydrolysis time beyond 2 h or from increasing
the temperature (data not shown). Choosing the shortest pos-
sible hydrolysis time will also increase the throughput of the
method. Figure 1 presents the increase (or decrease) of the
concentration (as reflected by the changes of the peak area)
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in the sample after hydrolysis compared with prior to the hy-
drolysis for a selected panel of compounds. Significant in-
creases were observed for the F-series IsoPs—all three en-
zymes increased the metabolite levels by more than 50 %.
Some downstream metabolites, 8-iso-13,14-dihydro-PGF2α
and 13,14-dihydro-PGF2α, were exclusively detected after
GUS hydrolysis (Fig. 1b). No significant increase in the E-
series PGs compared with the free levels were found after
GUS hydrolysis. The NO2-FAs mediators could not be
analysed after hydrolysis due to their extreme temperature
and enzymatic lability (see below for further discussion). No
significant differences in the hydrolysis efficiency were found
between the three GUSs for the pre-selected panel of com-
pounds. Our final choice of the GUS for our protocol was
finally made based on encountered blank effects of GUSs
and metabolite stability in presence of the GUS (see below).
The enzyme blank effect
We identified an important and so far unreported observation
related to an oxidised lipid background present within the
three GUSs, especially for H. pomatia. Evaluation of the en-
zyme blank samples, which consisted of water following the
GUS hydrolyses sample workup, revealed the presence of an
oxidised lipid background. In Fig. 2, we show the LC-MS/MS
trace for PGF2α and PGE2 in the non-hydrolysed urine sam-
ple, GUS blank samples and procedure blank sample (water
sample extracted by LLE, no enzyme added). Figure 2a shows
there is no signal for PGF2α in the procedure blank sample
while a high level of PGF2α were found especially in the
H. pomatia GUS blank sample. The levels of PGF2α in
E. coli and bovine liver GUS samples were lower compared
with the high PGF2α background present in H. pomatia.
Similar observations are made for PGE2 (Fig. 2b). For the
selected panel of oxidised lipids, the enzyme blank effect is
presented by the area ratio between the blank enzyme sample
and the hydrolysed sample at 2 h (Areain enzyme blank sample/
Areain 2 h hydrolysed sample). Inspection of the complete IsoP, PG
and NO2-FA target panel found that H. pomatia GUS
contained the highest blank effect compared with E. coli and
bovine liver (see ESM Table S7). Based on this observation,
H. pomatia was not considered a suitable GUS candidate to
measure the total urinary oxidised lipid profile.
Internal standard stability
Beside the enzyme blank effect, the stability of the ISTDs during
the 2 h incubation at 37 °Cwas investigated as representative for
their respective endogenous metabolite classes. The percentage
change for the ISTDs treated with the three different enzymes in
2 h compared with 0 h were determined and are shown in Fig. 3.
ISTDs representing the F-series PGs and IsoPswere identified as
stable at 37 °C, over 2 hwith the addition of an enzyme included,
showing less than 10 % change in their levels. However, the E-
andD-series PG ISTDs showed temperature sensitivity, especial-
ly PGD2-d4. Reversely, the A-series PG ISTDPGA2-d4 showed
increasing concentrations, possibly due to PGD2-d4 spontaneous
dehydration forming PGA2-d4. The 10-NO2-Oleic acid d17
(NO2-FAs ISTD) showed hypersensitivity to hydrolysis condi-
tions (buffer and temperature), showing a 40%decrease in levels
within 2 h compared with non-hydrolysed sample. Furthermore,
the addition of all three enzymes resulted in a more pronounced
decrease (70 to 90%), explaining the above-mentioned decrease
of endogenous NO2-FAs during enzymatic hydrolyses. Overall,
Fig. 1 Changes in response of the selected panel of compounds in the
urine samples after 2 h enzymatic hydrolysis (at 37 °C with E. coli,
H. pomatia or bovine liver GUS) compared with non-hydrolysed samples
(no GUS). A y-axis represents the normalised peak area of a metabolite
normalised to the mean area of the corresponding peak in non-hydrolysed
urine.B y-axis represents the peak area without normalisation since 8-iso-
13,14-dihydro-PGF2α and 13,14-dihydro-PGF2αwere exclusively detect-
ed in GUS-hydrolysed urine. Error bars indicate standard deviation
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thehydrolysisusingGUSfromE.coli showedthe largestpercent-
age change for the evaluated ISTDs, suggesting that the 75 mM
phosphatebuffer (pH6.8) orE. coliGUSaffect compound stabil-
ity. Although, bovine liver GUS showed similar ISTD stability
compared withH. pomatia, the latter’s significant enzyme blank
effect led to bovine liver being chosen as our preferred hydrolys-
ing enzyme. Furthermore, bovine liver GUS also resulted in the
inclusion of D- and A-series PGs in the target list. Therefore, we
chosebovineliver-derivedGUShydrolysingat37°Cfor2hasthe
optimal procedure for analysing theurinaryoxidised lipidprofile.
Increasing the metabolite scope
Using the optimised bovine liver hydrolysesmethod, we investi-
gated the potential to broaden the scope of the measurable
oxidised urinary lipid profile. We targeted the metabolites from
Fig. 2 The enzymatic oxidised lipid background (enzyme blank effect).
LC-MS/MS chromatograms representing the procedure blank (green),
followed by the three enzyme blank samples (E. coli, bovine liver and
H. pomatia), and the free urine levels (blue) are overlaid for (A) PGF2a
and (B) PGE2, respectively.H. pomatia GUS shows a high oxidised lipid
background. Samples were monitored for PGF2αm/z 353.2→ 193.2) and
PGE2 (m/z 351.2→ 271.2)
Fig. 3 The stability of the IsoP,
PG and NO2-FA ISTDs during
the 2-h hydrolyses. The
percentage changes of ISTD
levels (compare 2 with 0 h) were
investigated to evaluate the
stability of each ISTD. Overall,
ISTDs with bovine liver GUS
hydrolysis indicated the highest
degree of stability. The vertical
dotted lines indicate 10% change.
x-axis indicates percentage
changes of ISTD areas between 2
and 0 h (area2 h-ISTD/area0 h-
ISTD) × 100 %. Error bars
indicate standard deviation
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auto-oxidation, COX, LOX and CYP450 pathways and com-
pared the amount of free oxidised lipids (from non-hydrolysed
urine) with the total amount of oxidised lipids (from hydrolysed
urine).Therewere51metabolitesdetected inbothhydrolysedand
non-hydrolysed samples, of which 23 metabolites were signifi-
cantly increased by hydrolysis. More importantly, 27 additional
oxidisedlipidsweredetectedexclusivelyinthetotaloxidisedlipid
analysis (Table 1). As shown in Table 1, wewere able to increase
the scope of the method by using an enzymatic hydrolysis ap-
proach to measure the total urinary oxidised lipid signature, pro-
viding amore complete picture for biological interpretation.
Method validation
Validation measurements were performed using pooled urine
as a sample matrix. Recovery, matrix effect and batch-to-batch
precision were determined.
Recovery and ion suppression
The performances of the analytical methods (free and total
oxidised lipid profiling) with respect to recovery (of the free
forms) and ion suppression were validated for those metabo-
lites which were available as deuterium-labelled compounds
and which were usually used as ISTDs. For determining re-
coveries, samples were independently spiked before or spiked
after the extraction procedure with ISTDs, and the area ratios
between these samples (Areaspike before/Areaspiked after) were
calculated as the recoveries. Figure 4a demonstrates that re-
coveries are from 85 to 115 % for most ISTDs, indicating the
effectiveness of both procedures to extract the oxidised me-
tabolome from urine samples. The non-hydrolysed samples
(free levels) with a simpler sample handling procedure
showed slightly higher recoveries compared with the hydro-
lysed procedure (total levels) except for the nitro-fatty acid
Table 1 Urinary oxidised lipids measured by bovine liver GUS hydrolysis and non-hydrolysis methods
RNS ROS COX LOX CYP450
Detected in both GUS-hydrolysed
and GUS-non-hydrolysed urine
11-HDoHE* 13,14-dihydro-15-keto-PGE2* 12S-HEPE 12,13-DiHOME*
14-HDoHE 15-keto-PGF1α 20-carboxy-LTB4
# 12,13-EpOME*
5-iPF2α- VI* 2,3-dinor-11b-PGF2α* 5S,6R-LipoxinA4 14,15-DiHETrE*
8,12-iPF2α- IV* 2,3-dinor-8-iso-PGF2α* 11-HETE 8,9-DiHETrE*
8-iso-15(R)-PGF2α* 20-hydroxy-PGE2
# 11-trans-LTD4# 9,10-DiHOME*
8-iso-15-keto-PGF2α* Δ12-PGJ2* 12-HETE 9,10-EpOME*
8-iso-PGE1
# Δ17, 6-ketoPGF1α* 13-HODE*
8-iso-PGE2 PGA2 13-KODE
8-iso-PGF1α PGD1
# 15-HETE*
8-iso-PGF2α * PGD2
# 5-HETE
PGE1
# 9,10,13-TriHOME*
PGE2 9,12,13-TriHOME*
PGE3 9-HODE
PGF1α 9-HOTrE
PGF2α* 9-KODE
PGF3α LTD4*
PGJ2
#
Tetranor-PGEM#
Detected in GUS hydrolysed urine
exclusively
10-HDoHE 13_14-dihydro-PGF2α 15S-HETrE 20-HETE
8-iso-13,14-dihydro-PGF2α 13,14-dihydro-15-keto-PGD2 15-HpETE 12,13-DiHODE
8-iso-15-keto-PGF2β 13,14-dihydro-15-keto-PGF2α 5S,15S-DiHETE 19,20-DiHDPA
9-HETE 15-deoxy-delta-12,14-PGD2 5S,6S-Lipoxin A4 11,12-DiHETrE
15-keto-PGF2α 5S-HEPE 11,12-EpETrE
16-HDoHE 5S-HpETE 14,15-DiHETE
bicyclo-PGE2 9-HEPE 17,18-DiHETE
PGK2 5,6-DiHETrE
Detected in non-hydrolysed urine
exclusively
NO2-αLA
NO2-LA
NO2-OA
*Significantly increased with hydrolysis; # significantly decreased with hydrolysis
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ISTD (10-NO2-oleic acid-d17 as discussed in BInternal stan-
dard stability^).
To determine the ion suppression caused by the pres-
ence of compounds of the matrix, ISTD areas in urine
samples spiked after the total and free oxidised lipid
extractions were compared with the ISTD areas in injec-
tion solution. Ion suppression values shown in Fig. 4b
ranged between 0.5 and 1 for most of the metabolites;
values below 1 indicate the presence of ion suppression
caused by co-eluting compounds from the urine matrix
that were not removed by the sample preparation and
that affect the ionisation of those targeted metabolites
[35]. Three ISTDs with high ion suppression (lower than
0.5) were PGA2-d4, 6-ketoPGF1-d4 and TBX2-d4.
However, ion suppression effects are corrected through
the deuterated ISTD normalisation (Areametaboli te/
AreaISTD) as both the metabolite and its corresponding
ISTD experience similar ion suppression.
Precision and batch-to-batch effect
To be able to reproducibly and accurately report the
oxidised lipid metabolome from patient urine samples,
it is important to estimate the analytical variation.
Therefore, the intra-batch precision and inter-batch
variability were assessed for all endogenous oxidised
lipids. Precision is dependent on extraction reproducibil-
ity, injection variation and detector stability, while the
inter-batch variability is influenced by the robustness of
the chromatography and instrument stability across dif-
ferent measurement days (n = 3).
In ESM Fig. S3a, the precision (intra-batch RSD) and
in ESM Fig. S3b, the batch-to-batch effect (inter-batch
RSD) of endogenous metabolites obtained from
hydrolysed/non-hydrolysed urine samples are shown.
Investigating the precision for the non-hydrolysed proce-
dure showed that 59 % of metabolites had the RSD <
15 %, with a further 25 % of metabolites having a RSD
between 15 and 30 %. The hydrolysed procedure showed
improved precision with 66 % of metabolites having the
RSD < 15 % and 29 % of metabolites having a RSD
between 15 and 30 %. The increased precision observed
in the hydrolysed procedure can be attributed to in-
creased metabolite concentrations, leading to more accu-
rate detection, while the higher variation in the non-
hydrolysed procedure was predominantly driven by low
abundant compounds. Both procedures performed equal-
ly well in batch-to-batch effects, indicative of a stable
and reproducible LC-MS analyses across three measure-
ment days.
Fig. 4 Performance characteristics of sample preparation. Deuterium-labelled ISTDs were evaluated for (A) recovery and (B) ion suppression; values
below 1 indicate presence of ion suppression (B)
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Application
Subjects
For the present study, baseline urine samples from RA
patients who were treated with TNF-α inhibitors (ETN
or ADA) were selected based on good response or non-
response after 3 months of therapy. The baseline charac-
teristics of 80 patients are shown in Table 2. Subjects
had a mean age of 53.8 years, a median disease duration
of 5 years and had previously taken a mean of two con-
comitant disease-modifying anti-rheumatic drugs (co-
DMARDs). Subjects were mainly female (58 females,
22 males). Good responders had higher baseline DAS28
(4.8 ± 0.9 compared with 4.2 ± 11, P = 0.006) and C-
reactive protein (CRP) levels (8 ± 11 compared with 5 ±
7, P = 0.04) compared with the non-responders. There
were no significant differences between the other
parameters.
Detection of oxidised lipids in human urine
Applying total and free oxidised lipid profiling to ran-
domly collected urine samples, we are able to detect 67
metabolites in hydrolysed urine samples and 44 in non-
hydrolysed urine samples. There were 97 % total and
95 % free oxidised lipid metabolites measured with a
RSD < 30 % (see ESM Table S8). Because the total
oxidised lipid profiling provides a larger scope of metab-
olites, we focused on the total urinary oxidised lipid
profiles (after hydrolysis), in addition to the free NO2-
FAs levels measured in the analyses without hydrolysis
in the subsequent data analyses and interpretation.
Relationships between total oxidised lipids profiling
and RA-associated parameters
To investigate the relationship between RA-associated param-
eters and total oxidised lipid levels, repeated assessments
using multiple linear regression (MLR) models were per-
formed on individual metabolite. Confounding factors (age,
sex, BMI, smoking status, alcohol consumption, co-
DMARDs) and RA-associated parameters (baseline DAS28,
CRP and DAS28 improvement) were added into MLR as
independent variables, and the oxidised lipid level was set as
the dependent variable. RA-associated parameters which were
correlated with oxidised lipid levels (P < 0.10) were selected
(Table S9) and are visualised by Cytoscape in Fig. 5. CRP
showed a positive correlation with 16-HDoHE (P = 0.027)
and a negative correlation with PGD3 (P = 0.026); DAS 28
showed a positive association with 14,15-DiHETE (P =
0.036) and 5S, 6R-LipoxinA4 (P = 0.005); DAS28 improve-
ment (DAS28month 0 −DAS28month 3) showed significantly
positive association with PGF3α (P = 0.017), PGF2α (P =
0.018), iPF2a IV (P = 0.021), 11,12-EpETrE (P = 0.040), 11-
HETE (P = 0.019), 14,15-DiHETrE (P = 0.017) and 14-
HDoHE (P = 0.033). Since NO2-FAs were labile in the hydro-
lysing procedure, we included the free NO2-αLA, NO2-LA
and NO2-OA levels during the MLR. These three metabolites
were all negatively associated with baseline DAS28
(P < 0.05).
Discussion
In the present study, we optimised and validated a GUS-based
hydrolysis method to evaluate the oxidised urinary lipid
Table 2 Baseline characteristics of the study subjects (n = 80), subdivided according to the therapeutic response at 3 months
All subject
(n = 80)
Non-response
(n = 40)
Good response
(n = 40)
P value (good responders
vs. non-responders)
Gender (female, n (%)) 58 (72.5) 31 (77.5) 27 (67.5) 0.453
Age (mean (SD)) 53.8 (11.0) 52.7 (11.3) 55.1 (10.8) 0.461
Disease duration (median (IQR)) 5 (8.0) 5 (7.0) 6 (9.0) 1.000
Smoking currently (n (%)) 23 (28.7) 12 (30.0) 11 (27.5) 0.805
Alcohol >7 units/week (n (%)) 16 (20.3) 5 (12.5) 11 (27.5) 0.099
BMI (mean (SD)) 26.9 (5.3) 27.1 (5.0) 26.7 (5.6) 0.874
RF (positive, n (%)) 57 (71.3) 26 (65.0) 31 (77.5) 0.323
ACPA (positive, n (%)) 57 (71.3) 26 (65.0) 31 (77.5) 0.323
Baseline DAS28 (mean (SD)) 4.5 (1.0) 4.2 (1.1) 4.8 (0.9) 0.006
CRP (median (IQR)) 7 (10.0) 5 (8) 8 (11.0) 0.045
SD standard deviation, IQR interquartile range
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profile. We demonstrated that the number of measured
oxidised lipids were approximately twofold increased after
hydrolysing with bovine liver-sourced GUS. Furthermore,
we applied the method to urine samples from patients with
RA and identified oxidised lipids associated with RA-
associated parameters important in determining therapeutic
response.
As a non-invasive biological matrix, urine is easily collect-
ed and can effectively be used as an oxidised lipids readout.
However, urine does present some challenges including dilu-
tion effect (morning sample, 24 h sample, random sample),
glucuronidation of metabolites with low solubility, and a high
salt concentration etc. Although some of these challenges can
be addressed with proper experimental planning and
standardised sample collection procedures, the choice be-
tween analysing free or total levels of oxidised lipids still
needs to be addressed. Thus, we developed a robust enzymatic
method to hydrolyse the GlcA-conjugated oxidised lipids,
obtaining the total oxidised lipid profile for urine samples.
During the method development, we found an enzyme blank
effect in the three candidate enzymes (see ESM Table S7)
which needs to beminimised in order to avoid adding artefacts
which could interfere with the biological interpretation of the
results.
Several different GUS are available commercially for re-
search purposes, with each enzyme having its own specific
characteristics properties relating to substrate affinities and
efficiency. Our choice of candidate enzymes was guided by
selecting those previously reported in literature [18, 30, 31].
H. pomatia GUS was the most widely used enzyme but had a
very prominent blank effect. The oxidised lipid background
might be derived from inadequate purifying and cleaning pro-
cedures used during enzyme extraction and isolation. While
this might not be true for all forms of GUS derived from
H. pomatia, we decided against the use of H. pomatia as the
background might influence our biological interpretation of
the data.
Comparing the total and free oxidised lipid profiles re-
vealed increased levels, especially in the F-series IsoPs, F-
series PGs, hydroxy-fatty acids and dihydroxy-fatty acids,
while having minimal effect on E-series PGs in the total
oxidised lipid profile. The lack of effect on the E-series PGs
could be explained in a study done by Little et al., where they
investigated the different human recombinant UDP-
glucuronosyltransferases and found that only one isoform
UGT2B7 was capable of forming PGE2 glucuronide [17].
UGT2B7 were exclusively found in the colon, and faeces
rather than urine might contain high levels of E-series glucu-
ronide conjugates. The significant increase in LOX and
CYP450 metabolites might be due to their increasing hydro-
phobic nature, with glucuronidation increasing their urinary
excretion. Similar to our findings, Prakash et al., reported
significant increase in the level of 20-HETE, an CYP450 me-
tabolite in urine treated with β-glucuronidases, and they con-
cluded that CYP450 metabolites are predominantly excreted
in conjugated form [13]. Whereas the method reported by
Newman et al. needed 4 mL of urine to measure the free
CYP450-oxidised lipid metabolites [22], using our bovine
liver hydrolysis method, we could evaluate the same
CYP450 pathway metabolites by using ten times less urine.
Optimising the extraction and analyses of the anti-
inflammatory NO2-FAs will aid us in studying the field of
Fig. 5 Correlations between
rheumatoid arthritis-associated
clinical parameters and oxidised
lipid levels with P < 0.10 based
on multiple linear regression
analyses
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nitrosative stress. A disappointing finding was our inability to
accurately measure the total NO2-FAs levels, due to their la-
bile nature. Although, we were able to effectively measure the
free NO2-αLA, NO2-LA and NO2-OA levels in urine. In a
work published by Salvatore et al., they showed the presence
of cysteine-NO2-FA conjugates in urine and used a short
chemical (HgCl2) hydrolysis procedure at 37 °C to measure
its total levels [36]. Thus, to accurately measure the total NO2-
FA level identification of the primary conjugated form needs
to be done, followed with optimised chemical hydrolyses.
For the urine samples from RA patients, which were col-
lected at a random time of day, we used the urinary creatinine
level for correcting the oxidised lipids for sample dilution.
Samples were retrospectively divided into good or no re-
sponders to therapy based on EULAR response criteria.
However, the subjects could not be separated into non-/good
response groups based on their baseline urinary oxidised
lipids profile and clinical parameters using categorical princi-
ple components analysis (CATPCA, score plot is shown in
ESM Fig. S4). After correcting for confounding factors (age,
sex, BMI, smoking status, alcohol consumption, co-
DMARDs), the urinary oxidised lipid readout did show asso-
ciations between inflammation and oxidative stress and clini-
cal parameters (CRP, 3-month DAS28 improvement, baseline
DAS28). C-reactive protein is an acute-phase inflammatory
protein, which showed a positive correlation with 16-
HDoHE, a docosahexaenoic acid (DHA) lipid peroxidation
metabolite. DHA showed efficacy as an anti-inflammatory
treatment when used as a prophylactic treatment in a mouse
RA model [37], thus the increased peroxidation of DHA
catalysed by ROS reduces the body’s anti-inflammatory ca-
pacity. Oxidative stress has been identified as an aggravator of
damage caused to bone in cartilage in RA [38, 39], so its
correlation with CRP underscores this relationship.
DAS28 is the most widely used measurement for assessing
the disease activity (swelling and tenderness in 28 joints, the
ESR and VAS general health) in RA [40]. In the present study,
good responders had higher baseline DAS28 compared with
non-responders. Clinically, it has been observed that a patient
with severe RA has high DAS28 and is more likely to obtain
therapeutic response [41]. Veselinovic et al. reported increased
levels of RNS in patients with high disease activity in serum
[38], while we found in urine that the downstream anti-
inflammatory NO2-FAs correlated negatively with DAS28.
This observation could be explained through the complex re-
lationship between RNS species, the beneficial signalling abil-
ities of RNS-nitrated lipid metabolites (NO2-FAs) and the
body’s anti-oxidant capacity. The positive correlation of
DAS28 improvement with strong pro-inflammatory media-
tors PGF2α, PGF3α and oxidative stress markers iPF2α-IV,
11-HETE and 14-HDoHE indicates the higher disease burden
within these baseline patients. The correlation of DAS28 and
its improvement with the anti-inflammatory CYP-450
dihydroxy-fatty acids metabolites and the LOX derived
LXA4 possibly reflects the intact innate anti-inflammatory
pathways in these patients still trying to lessen the RA disease
burden. The dihydroxy-fatty acids, 14,15-DiHETE, 11,12-
EpETrE and 14,15-DiHETrE are able to attenuate pro-
inflammatory pathways through activating and signalling via
the PPAR-gamma pathway [42]. The urinary oxidised lipid
profile of RA patients indicates the complex nature of the
disease with oxidative stress and inflammation having an in-
timate relationship with clinically measured parameters.
Conclusions
In the present study, we thoroughly explored different
deglucoronidation methods for urinary oxidised lipids and
developed a bovine liver GUS hydrolysing sample prepara-
tion method coupled with LC-MS to analyse the total urinary
oxidised lipid profile. With bovine liver GUS hydrolysis, we
are able to zoom into the urinary oxidised lipid metabolome,
providing a readout for inflammation and oxidative stress. Our
method detected more than 70 oxidised lipids in urine sam-
ples, biosynthesised from two non-enzymatic and three enzy-
matic pathways. The total oxidised lipid profiling method was
developed and validated for human urine and was demonstrat-
ed on patients with RA. The urinary oxidised lipid profile of
RA patients indicates the complex nature of the disease with
oxidative stress and inflammation having an intimate relation-
ship with clinically measured parameters. In conclusion, the
hydrolysed method developed here allows specific and sensi-
tive quantitative assessment of more than 70 oxidised lipids,
which expands the scope of compounds in urinary metabolic
profiling and may have wider applications in studies elucidat-
ing the role of these potent bioactive metabolites in human
diseases.
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